Matrix metallopeptidase 12

macrophage elastase
Identifiers
EC no.3.4.24.65
CAS no.146888-86-0
Databases
BRENDAenzyme data
ExPASyNiceZyme view
KEGGenzyme entry
MetaCycmetabolic pathway
Rheareactions
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
Search
PMCarticles
PubMedarticles
NCBIproteins
MMP12
Identifiers
AliasesMMP12, HME, ME, MME, MMP-12, Matrix metallopeptidase 12
External IDsOMIM: 601046; MGI: 97005; GeneCards: MMP12
Available structures
PDBOrtholog search: PDBe RCSB
Enzyme activity
EC #BRENDAExPASyKEGGMetaCyc
3.4.24.65↗↗↗↗
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_002426

NM_008605
NM_001320076
NM_001320077

RefSeq (protein)

NP_002417

NP_001307005
NP_001307006
NP_032631

Location (UCSC)Chr 11: 102.86 – 102.87 MbChr 9: 7.34 – 7.37 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

Matrix metalloproteinase-12 (MMP-12) also known as macrophage metalloelastase (MME) or macrophage elastase (ME) is an enzyme that in humans is encoded by the MMP12 gene.

Function

Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins. The prodomain is cleaved by extracellular proteinases when the enzyme is activated. The active enzyme is constituted by two domains, the catalytic domain responsible for its enzymatic activity and the hemopexin-like domain that in some MMPs plays a role in substrate recognition and can contribute to increasing catalytic efficiency. It is thought that the protein encoded by this gene is cleaved at both ends to yield the active enzyme, but this processing has not been fully described. The enzyme degrades soluble and insoluble elastin. The gene is part of a cluster of MMP genes which localize to chromosome 11q22.3.

Clinical significance

MMP12 may play a role in aneurysm formation and studies in mice and humans suggest a role in the development of emphysema.

Linvemastat (FP-020) and aderamastat (FP‑025) and are MMP12 selective inhibitors that are being evaluated for the treatment of asthma.